matthew galsky, md, tells us about the design and outcomes of the ev-301 trial from asco gu '21
Published 3 years ago • 33 plays • Length 2:01
Download video MP4
Download video MP3
Similar videos
-
2:53
matthew galsky, md, elaborates on outcomes from the checkmate 274 trial
-
4:22
dr. matthew galsky - asco 2021
-
3:31
matthew galsky, md, on the role of pd-l1 testing in previously untreated, locally advanced or muc
-
3:07
jeanny b. aragon-ching, md, facp, shares the design and outcomes of the ev-301 clinical trial
-
1:59
dr. matthew galsky on a post-treatment nomogram in urothelial cancer
-
1:10
matthew galsky, md, tells us about the phase 3 imvigor130 study in advanced urothelial cancer
-
2:30
matthew galsky, md, discusses the practice-changing potential of the profound study from esmo 2020
-
2:36
matthew galsky, md, on the checkmate-274 study in high risk, muscle-invasive urothelial carcinoma
-
40:57
case presentation on carcinoma gall bladder
-
14:58
2021 west oncology | genitourinary cancers | update on non-muscle invasive bladder cancer
-
41:43
the histologic variants of bladder cancer
-
44:28
breakthroughs in bladder cancer immunotherapy, with matthew galsky
-
1:07
dr. petrylak on the results of the ev-103 trial in bladder cancer
-
1:35
matthew galsky gives an overview of bladder cancer
-
1:03
dr. inman discusses the biology of bladder cancer
-
1:08
matthew galsky, md, shares a message for patients regarding clinical progress in bladder cancer
-
1:58
matthew galsky, md, considers the implications of the imvigor130 clinical study
-
2:04
areas of unmet need in metastatic urothelial carcinoma
-
5:40
highlights in bladder cancer from asco gu 2021
-
0:53
arlene siefker-radtke, md, discusses key takeaways from the ev-301 study in urothelial cancer
-
0:59
dr. galsky on progression on immunotherapy in bladder cancer
-
32:26
07 immunotherapy for bladder cancer what is standard and what is the future prof m galsky
Clip.africa.com - Privacy-policy